Table 4.

Percent change in sCTX from baseline to day 16 (pharmacodynamic population; Group A: midazolam + denosumab^*)

	Mean	SD	Minimum	Quartile 1	Median	Quartile 3	Maximum
% Change in sCTX†	–81.22	16.33	–95.4	–91.45	–87.52	–80.01	–43.4

sCTX, serum C-telopeptide.

^*Midazolam 2 mg orally on day 1 and day 16, and denosumab 60 mg subcutaneously on day 2.

^†Including values below the lower limit of quantification (0.2 ng/mL) but above the limit of detection (0.05 ng/mL).